帕曲妥单抗 T76796

Product Introduction
Bioactivity


英文名: Patritumab

描述: Patritumab（U3-1287）是抗 HER3 单克隆抗体，具有潜在的抗肿瘤活性，对 EGFR，HER2，HER3，ERK 和 AKT 的磷酸化有抑制作用和。Patritumab 促使细胞凋亡 (apoptosis)，抑制非小细胞肺癌的增殖。

体外活性: Patritumab targets the extracellular domain (ECD) of HER3 and induces apoptosis in DiFi-HRG4 cells (10 μg/mL; 5 days)[1]. Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT in DiFi-HRG4 cells without affecting that of ERK[1]. Additionally, Patritumab (10 μg/mL; 48 h) induces the cleavage of PARP, accompanied by both up-regulation of BIM and down-regulation of survivin expression[1].

体内活性: In a DiFi-HRG tumor xenografts model in mice, Patritumab (1 mg/mouse; intraperitoneal; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity[1]. Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1].

存储条件: store at low temperaturestore at -20°C

相关产品: Bufarenogin | Deltonin | Boehmenan | Laxiflorin B-4 | Cornuside | Epiberberine | Isochamaejasmine | DMU-212 | Avicularin | MK-8353

帕曲妥单抗 T76796信息由TargetMol中国为您提供，如您想了解更多关于帕曲妥单抗 T76796报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途